Full Breakdown
FDA Approves Lilly’s Mounjaro for Cardiovascular Risk Reduction in Type 2 Diabetes
8/28/2026, 8:29:59 PM
FDA Approval Expands Mounjaro’s Indications
On August 28, the U.S. Food and Drug Administration approved Eli Lilly’s diabetes medication Mounjaro for an additional indication: lowering the risk of heart attack or stroke in adults with type 2 diabetes who are at high risk for cardiovascular events. The drug, which targets the GLP-1 protein, is already marketed for weight-loss under the brand name Zepbound.
Trial Results Behind the Decision
The approval was based on a large head-to-head clinical trial that compared Mounjaro with Lilly’s older diabetes drug Trulicity. According to Lilly, the study showed Mounjaro reduced major adverse cardiovascular events by 8 % more than Trulicity, demonstrating a statistically significant advantage in preventing heart attacks and strokes.
Market Impact and Competitive Landscape
Lilly reported that sales of Mounjaro rose 91 % to $9.94 billion in the second quarter, driven by strong demand across global markets. The company’s move follows a series of FDA approvals for GLP-1 drugs from its Danish rival Novo Nordisk, which secured clearance for the weight-loss therapy Wegovy in 2024 and for its diabetes drug Rybelsus in 2025 to lower heart-risk in diabetic patients. Both firms are expanding the therapeutic reach of GLP-1 agents into cardiovascular disease and other conditions such as liver disorders.
Official Statements & Responses
Eli Lilly said the new indication reflects the company’s commitment to addressing the cardiovascular complications that drive mortality in type 2 diabetes. The FDA’s decision was presented as a validation of the trial data and an endorsement of the drug’s safety and efficacy profile for high-risk patients.
Implications for Diabetes Care
The expanded label positions Mounjaro as a dual-benefit therapy, offering glycemic control alongside cardiovascular protection. If adoption mirrors the recent sales surge, the approval could shift prescribing patterns toward GLP-1 agents for patients with both diabetes and elevated heart-risk, further intensifying competition among manufacturers seeking to broaden the clinical applications of this drug class.
